FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 268 filers reported holding FATE THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 1.51 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $40,000 | -9.1% | 636 | -64.5% | 0.00% | – |
| Q2 2022 | $44,000 | -36.2% | 1,791 | 0.0% | 0.00% | – |
| Q1 2022 | $69,000 | -96.1% | 1,791 | -94.1% | 0.00% | -100.0% |
| Q4 2021 | $1,766,000 | +1.2% | 30,183 | +2.5% | 0.00% | 0.0% |
| Q3 2021 | $1,745,000 | -68.0% | 29,446 | -53.2% | 0.00% | -75.0% |
| Q2 2021 | $5,460,000 | +3.8% | 62,907 | -1.4% | 0.00% | -42.9% |
| Q1 2021 | $5,262,000 | -22.9% | 63,826 | -15.0% | 0.01% | -30.0% |
| Q4 2020 | $6,828,000 | +148.6% | 75,089 | +9.3% | 0.01% | +100.0% |
| Q3 2020 | $2,747,000 | +13.1% | 68,713 | -2.9% | 0.01% | +25.0% |
| Q2 2020 | $2,428,000 | +26877.8% | 70,776 | +10010.9% | 0.00% | – |
| Q4 2018 | $9,000 | -40.0% | 700 | -22.2% | 0.00% | – |
| Q3 2018 | $15,000 | -59.5% | 900 | -72.7% | 0.00% | – |
| Q2 2018 | $37,000 | +236.4% | 3,300 | +83.3% | 0.00% | – |
| Q4 2017 | $11,000 | – | 1,800 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Polaris Venture Management Co. V, L.L.C. | 569,889 | $51,820,000 | 67.63% |
| Johnson & Johnson Innovation - JJDC, Inc. | 3,379,064 | $307,258,000 | 39.62% |
| Darwin Global Management, Ltd. | 952,847 | $86,642,000 | 24.18% |
| Redmile Group, LLC | 12,629,737 | $1,148,422,000 | 13.91% |
| DAFNA Capital Management LLC | 334,360 | $30,403,000 | 9.05% |
| Casdin Capital, LLC | 3,050,000 | $277,337,000 | 8.22% |
| Grosvenor Holdings, L.L.C. | 1,459,517 | $132,714,000 | 7.23% |
| Copernicus Capital Management, LLC | 3,240 | $295,000 | 4.60% |
| Eversept Partners, LP | 399,499 | $36,326,444 | 4.26% |
| Ally Bridge Group (NY) LLC | 260,000 | $23,642,000 | 4.05% |